Repurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders
Neutrophil-mediated inflammation is a key feature of immune-mediated chronic skin disorders, but the mechanistic understanding of neutrophil involvement in these conditions remains incomplete. Dapsone, colchicine, and tetracyclines are established drugs within the dermatologist’s therapeutic armamen...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/14/12/1515 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846105581747699712 |
|---|---|
| author | Ludovica Franceschin Alessia Guidotti Roberto Mazzetto Jacopo Tartaglia Christian Ciolfi Mauro Alaibac Alvise Sernicola |
| author_facet | Ludovica Franceschin Alessia Guidotti Roberto Mazzetto Jacopo Tartaglia Christian Ciolfi Mauro Alaibac Alvise Sernicola |
| author_sort | Ludovica Franceschin |
| collection | DOAJ |
| description | Neutrophil-mediated inflammation is a key feature of immune-mediated chronic skin disorders, but the mechanistic understanding of neutrophil involvement in these conditions remains incomplete. Dapsone, colchicine, and tetracyclines are established drugs within the dermatologist’s therapeutic armamentarium that are credited with potent anti-neutrophilic effects. Anti-neutrophilic drugs have established themselves as versatile agents in the treatment of a wide range of dermatological conditions. Some of these agents are approved for the management of specific dermatologic conditions, but most of their current uses are off-label and only supported by isolated reports or case series. Their anti-inflammatory and immunomodulatory properties make them particularly valuable in managing auto-immune bullous diseases, neutrophilic dermatoses, eosinophilic dermatoses, interface dermatitis, and granulomatous diseases that are the focus of this review. By inhibiting inflammatory pathways, reducing cytokine production, and modulating immune responses, they contribute significantly to the treatment and management of these complex skin conditions. Their use continues to evolve as our understanding of these diseases deepens, and they remain a cornerstone of dermatological therapy. |
| format | Article |
| id | doaj-art-a3a749d89aaa4800af7ee62cb3cd98c0 |
| institution | Kabale University |
| issn | 2218-273X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj-art-a3a749d89aaa4800af7ee62cb3cd98c02024-12-27T14:13:40ZengMDPI AGBiomolecules2218-273X2024-11-011412151510.3390/biom14121515Repurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin DisordersLudovica Franceschin0Alessia Guidotti1Roberto Mazzetto2Jacopo Tartaglia3Christian Ciolfi4Mauro Alaibac5Alvise Sernicola6Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, ItalyDermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, ItalyDermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, ItalyDermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, ItalyDermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, ItalyDermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, ItalyDermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, ItalyNeutrophil-mediated inflammation is a key feature of immune-mediated chronic skin disorders, but the mechanistic understanding of neutrophil involvement in these conditions remains incomplete. Dapsone, colchicine, and tetracyclines are established drugs within the dermatologist’s therapeutic armamentarium that are credited with potent anti-neutrophilic effects. Anti-neutrophilic drugs have established themselves as versatile agents in the treatment of a wide range of dermatological conditions. Some of these agents are approved for the management of specific dermatologic conditions, but most of their current uses are off-label and only supported by isolated reports or case series. Their anti-inflammatory and immunomodulatory properties make them particularly valuable in managing auto-immune bullous diseases, neutrophilic dermatoses, eosinophilic dermatoses, interface dermatitis, and granulomatous diseases that are the focus of this review. By inhibiting inflammatory pathways, reducing cytokine production, and modulating immune responses, they contribute significantly to the treatment and management of these complex skin conditions. Their use continues to evolve as our understanding of these diseases deepens, and they remain a cornerstone of dermatological therapy.https://www.mdpi.com/2218-273X/14/12/1515dapsonecolchicinetetracyclineneutrophilsautoimmune bullous disorderspsoriasis |
| spellingShingle | Ludovica Franceschin Alessia Guidotti Roberto Mazzetto Jacopo Tartaglia Christian Ciolfi Mauro Alaibac Alvise Sernicola Repurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders Biomolecules dapsone colchicine tetracycline neutrophils autoimmune bullous disorders psoriasis |
| title | Repurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders |
| title_full | Repurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders |
| title_fullStr | Repurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders |
| title_full_unstemmed | Repurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders |
| title_short | Repurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders |
| title_sort | repurposing historic drugs for neutrophil mediated inflammation in skin disorders |
| topic | dapsone colchicine tetracycline neutrophils autoimmune bullous disorders psoriasis |
| url | https://www.mdpi.com/2218-273X/14/12/1515 |
| work_keys_str_mv | AT ludovicafranceschin repurposinghistoricdrugsforneutrophilmediatedinflammationinskindisorders AT alessiaguidotti repurposinghistoricdrugsforneutrophilmediatedinflammationinskindisorders AT robertomazzetto repurposinghistoricdrugsforneutrophilmediatedinflammationinskindisorders AT jacopotartaglia repurposinghistoricdrugsforneutrophilmediatedinflammationinskindisorders AT christianciolfi repurposinghistoricdrugsforneutrophilmediatedinflammationinskindisorders AT mauroalaibac repurposinghistoricdrugsforneutrophilmediatedinflammationinskindisorders AT alvisesernicola repurposinghistoricdrugsforneutrophilmediatedinflammationinskindisorders |